コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 The primary end point was to determine the maximal tolerated dose.
2 ogenesis in preclinical models; however, the maximal tolerated dose and safety of direct epicardial a
3 hange in the FAQLQ-PF was independent of the maximal tolerated dose at baseline or following four mon
11 ims of this phase 1 study were to define the maximal tolerated dose (MTD), dose-limiting toxicities (
13 response rate of paclitaxel administered at maximal tolerated doses (MTD) in patients with newly dia
15 ory prostate cancer (HRPC), to determine the maximal-tolerated dose (MTD) of Cy in this regimen, and
17 Therapy studies were performed using the maximal tolerated doses (MTDs) of (90)Y-DOTA-RS7 (3.9 MB
20 ages were acquired 1 h after infusion of the maximal tolerated dose of dobutamine and again during in
21 dose-escalation trial done to determine the maximal tolerated dose of NSC-CRAd-S-pk7, following a 3
23 under treatment with oral acetazolamide and maximal tolerated doses of topical anti-glaucoma medicat
27 ues of MFIS total scores at baseline and the maximal tolerated dose were as follows: 51.3 (95% CI 49.
28 ing as cancer treatment paradigms move from "maximal tolerated dose," which may promote therapy induc